NCT04515225

COVID-19 Prevalence in HIV-infected Patients

Seroprevalence of SARS-CoV-2 Antibodies Among Adult Patients Living With HIV

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them figuring different kinds of immune deficiency. Even if nowadays HIV infection is usually well controlled by ARV drugs, those patients with uncontrolled viral load and/or low CD4 cell counts, remain at higher risk of severe COVID infection. In this context, the primary objective of our study is aimed at evaluating the prevalence of SARS-CoV-2 antibodies in a cohort of HIV-infected patients followed-up in an HIV-infection care center. Secondary objectives are: evaluating whether the antibodies are protective or not, the kinetic of these antibodies, and HIV associated factors with the presence of antibodies.

Conditions

• HIV Infections

Interventions

Type	Name	Description
OTHER	Blood Sample	Blood Sample

Timeline

• Start date: 2020-11-04
• Primary completion: 2022-05-03
• Completion: 2022-05-03
• First posted: 2020-08-17
• Last updated: 2021-08-10

Locations

1 site across 1 country: France